Associations Between Perceived Stress and Chemotherapy-Induced Peripheral Neuropathy and Otoxicity in Adult Cancer Survivors

被引:38
作者
Miaskowski, Christine [1 ]
Paul, Steven M. [1 ]
Mastick, Judy [1 ]
Abrams, Gary [2 ]
Topp, Kimberly [2 ]
Smoot, Betty [2 ]
Kober, Kord M. [1 ]
Chesney, Margaret [2 ]
Mazor, Melissa [1 ]
Mausisa, Grace [1 ]
Schumacher, Mark [2 ]
Conley, Yvette P. [3 ]
Sabes, Jennifer Henderson [2 ]
Cheung, Steven [2 ]
Wallhagen, Margaret [1 ]
Levine, Jon D. [2 ,4 ]
机构
[1] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[3] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA
[4] Univ Calif San Francisco, Sch Dent, San Francisco, CA USA
基金
美国国家卫生研究院;
关键词
Stress; chemotherapy; peripheral neuropathy; hearing loss; tinnitus; cancer survivor; QUALITY-OF-LIFE; CHRONIC PAIN; HEARING-LOSS; EVENT SCALE; PSYCHOLOGICAL STRESS; TINNITUS SUFFERERS; SOCIAL SUPPORT; DEPRESSION; IMPACT; PREVALENCE;
D O I
10.1016/j.jpainsymman.2018.02.021
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. The most common adverse effects from neurotoxic chemotherapy are chemotherapy-induced neuropathy (CIPN), hearing loss, and tinnitus. Although associations between perceived stress and persistent pain, hearing loss, and tinnitus are documented, no studies have examined these associations in cancer survivors who received neurotoxic chemotherapy. Objectives. In this cross-sectional study, we evaluated for associations between perceived stress and the occurrence of CIPN, hearing loss, and tinnitus, in 623 adult cancer survivors who received platinum and/or taxane compounds. Methods. Survivors completed self-report measures of hearing loss, tinnitus, and perceived stress (i.e., Impact of Events Scale Revised LIES-RD. Separate logistic regression analyses were done for each neurotoxicity to evaluate whether each of the IES-R subscale (i.e., intrusion, avoidance, hyperarousal) and total scores made a significant independent contribution to neurotoxicity group membership. Results. Of the 623 survivors in this study, 68.4% had CIPN, 34.5% reported hearing loss, and 31.0% reported tinnitus. Older age, higher body mass index, poorer functional status, being born prematurely, cancer diagnosis, and higher intrusion (P = 0.013), hyperarousal (P = 0.014), and total (P = 0.047) IES-R scores were associated with CIPN. Older age, being male, poorer functional status, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.007) score were associated with hearing loss. Being male, having less education, a worse comorbidity profile, and a higher IES-R hyperarousal (P = 0.029) score were associated with tinnitus. Conclusion. These findings suggest that increased levels of perceived stress are associated with the most common chemotherapy-induced neurotoxicities. (C) 2018 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:88 / 97
页数:10
相关论文
共 50 条
  • [41] Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)
    Han, Yaqin
    Smith, Maree T.
    FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [42] Chemotherapy-induced Peripheral Neuropathy and Depression in Cancer Patients
    Kim, Kyung Yeon
    Lee, Seung Hee
    Oh, Pok Ja
    ASIAN ONCOLOGY NURSING, 2015, 15 (03) : 149 - 155
  • [43] Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer
    van Velzen, Merel J. M.
    Pape, Marieke
    Sprangers, Mirjam A. G.
    van Kleef, Jessy Joy
    Mostert, Bianca
    Beerepoot, Laurens, V
    Slingerland, Marije
    Gootjes, Elske C.
    Hoekstra, Ronald
    van de Poll-franse, Lonneke, V
    Mohammad, Nadia Haj
    van Laarhoven, Hanneke W. M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (07): : 455 - 461
  • [44] Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors
    Wong, Melisa L.
    Cooper, Bruce A.
    Paul, Steven M.
    Abrams, Gary
    Topp, Kimberly
    Kober, Kord M.
    Chesney, Margaret A.
    Mazor, Melissa
    Schumacher, Mark A.
    Conley, Yvette P.
    Levine, Jon D.
    Miaskowski, Christine
    SUPPORTIVE CARE IN CANCER, 2019, 27 (10) : 3905 - 3912
  • [45] Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
    Bao, Ting
    Basal, Coby
    Seluzicki, Christina
    Li, Susan Q.
    Seidman, Andrew D.
    Mao, Jun J.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (02) : 327 - 333
  • [46] Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing
    Zhi, W. Iris
    Chen, Patricia
    Kwon, Alice
    Chen, Connie
    Harte, Steven E.
    Piulson, Lauren
    Li, Susan
    Patil, Sujata
    Mao, Jun J.
    Bao, Ting
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (03) : 587 - 595
  • [47] Chemotherapy-induced peripheral neuropathy - epidemiology and pathogenesis
    Izycki, Dariusz
    Niezgoda, Adam
    Kaimierczak, Maciej
    Nowak-Markwitz, Ewa
    GINEKOLOGIA POLSKA, 2016, 87 (04) : 293 - 299
  • [48] Rodent Models of Chemotherapy-Induced Peripheral Neuropathy
    Hoeke, Ahmet
    Ray, Mitali
    ILAR JOURNAL, 2014, 54 (03) : 273 - 281
  • [49] The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy
    Cindy S. Tofthagen
    Andrea L. Cheville
    Charles L. Loprinzi
    Current Oncology Reports, 2020, 22
  • [50] Repurposing chemotherapy-induced peripheral neuropathy grading
    Velasco, Roser
    Argyriou, Andreas A.
    Cornblath, David R.
    Bruna, Pere
    Alberti, Paola
    Rossi, Emanuela
    Merkies, Ingemar S. J.
    Psimaras, Dimitri
    Briani, Chiara
    Lalisang, Roy I.
    Schenone, Angelo
    Cavaletti, Guido
    Bruna, Jordi
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (12)